Published in Nat Biotechnol on April 01, 2011
Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol (2012) 1.65
Exosomal miRNAs: Biological Properties and Therapeutic Potential. Front Genet (2012) 1.60
Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine (2012) 1.27
Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal (2013) 1.20
Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell (2013) 1.18
Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release (2015) 1.17
Exosomes as mediators of neuroinflammation. J Neuroinflammation (2014) 1.12
Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther (2012) 1.10
Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol (2013) 1.08
Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PLoS One (2013) 0.97
Exosomes and Their Role in the Life Cycle and Pathogenesis of RNA Viruses. Viruses (2015) 0.95
Bovine milk-derived exosomes for drug delivery. Cancer Lett (2015) 0.93
Progress on RNAi-based molecular medicines. Int J Nanomedicine (2012) 0.90
Exosomes as a Nanodelivery System: a Key to the Future of Neuromedicine? Mol Neurobiol (2014) 0.86
Effects of mesenchymal stromal cell-derived extracellular vesicles on tumor growth. Front Immunol (2014) 0.86
A comparison of two cellular delivery mechanisms for small interfering RNA. Physiol Rep (2015) 0.86
Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents. Small (2013) 0.86
Small non-coding RNAs transfer through mammalian placenta and directly regulate fetal gene expression. Protein Cell (2015) 0.83
Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci Rep (2015) 0.81
Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther (2016) 0.80
Targeted Lipid Profiling Discovers Plasma Biomarkers of Acute Brain Injury. PLoS One (2015) 0.80
EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. J Biomed Sci (2015) 0.80
Hijacking the Cellular Mail: Exosome Mediated Differentiation of Mesenchymal Stem Cells. Stem Cells Int (2016) 0.80
Post isolation modification of exosomes for nanomedicine applications. Nanomedicine (Lond) (2016) 0.78
Intravenous injection of microvesicle-delivery miR-130b alleviates high-fat diet-induced obesity in C57BL/6 mice through translational repression of PPAR-γ. J Biomed Sci (2015) 0.77
How can nanotechnology help membrane vesicle-based cancer immunotherapy development? Hum Vaccin Immunother (2012) 0.77
Perspectives on the Potential Therapeutic Uses of Vesicles. Exosomes Microvesicles (2015) 0.76
Emerging roles of extracellular vesicles in neurodegenerative disorders: focus on HIV-associated neurological complications. Cell Death Dis (2016) 0.76
Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics. ACS Nano (2017) 0.76
Automated Protein Localization of Blood Brain Barrier Vasculature in Brightfield IHC Images. PLoS One (2016) 0.76
Exosomes in cancer theranostic: Diamonds in the rough. Cell Adh Migr (2017) 0.75
MSCs-Derived Exosomes and Neuroinflammation, Neurogenesis and Therapy of Traumatic Brain Injury. Front Cell Neurosci (2017) 0.75
Exosomes as nanocarriers for siRNA delivery: paradigms and challenges. Arch Med Sci (2016) 0.75
Nanoscale Extracellular Vesicle Analysis in Alzheimer's Disease Diagnosis and Therapy. Int J Alzheimers Dis (2016) 0.75
Gene delivery: Designer DNA give RNAi more spine. Nat Nanotechnol (2012) 0.75
Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today (2015) 0.75
Use of single chain antibody derivatives for targeted drug delivery. Mol Med (2016) 0.75
Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PLoS One (2017) 0.75
Chaperonin-Dendrimer Conjugates for siRNA Delivery. Adv Sci (Weinh) (2016) 0.75
Identification and Characterization of 293T Cell-Derived Exosomes by Profiling the Protein, mRNA and MicroRNA Components. PLoS One (2016) 0.75
Potential Roles of Exosomal MicroRNAs as Diagnostic Biomarkers and Therapeutic Application in Alzheimer's Disease. Neural Plast (2017) 0.75
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature (2009) 5.00
Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell (2013) 3.92
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2009) 3.58
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol (2003) 2.87
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest (2009) 2.85
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity (2013) 2.79
Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol (2004) 2.39
TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity (2008) 2.37
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol (2005) 2.31
Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol (2010) 2.30
Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol (2005) 2.16
Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol (2010) 2.13
siRNA and isRNA: two edges of one sword. Mol Ther (2006) 2.02
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol (2004) 1.85
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell (2013) 1.82
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol (2002) 1.76
Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res (2005) 1.74
Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation. J Cell Biol (2005) 1.69
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem (2004) 1.61
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Approaching the RNA ligand for RIG-I? Immunol Rev (2009) 1.57
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res (2005) 1.49
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 1.47
Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res (2003) 1.44
IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol (2004) 1.40
Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol (2004) 1.35
Plasmacytoid dendritic cells: the key to CpG. Hum Immunol (2002) 1.28
The chase for the RIG-I ligand--recent advances. Mol Ther (2010) 1.27
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol (2009) 1.25
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol (2006) 1.23
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 1.19
Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol (2008) 1.18
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res (2013) 1.17
c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. J Virol (2009) 1.14
Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol (2002) 1.14
RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids. EMBO J (2012) 1.14
Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12
Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol (2009) 1.07
CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol (2005) 1.06
Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res (2011) 1.06
Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol (2009) 1.04
Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev (2012) 1.04
Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res (2007) 1.04
Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J Virol (2005) 1.03
Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands. J Immunol (2007) 1.02
RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol (2008) 1.01
Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol (2014) 0.99
Turning tumors into vaccines: co-opting the innate immune system. Immunity (2013) 0.99
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer (2006) 0.98
Analysis of plasmacytoid and myeloid dendritic cells in nasal epithelium. Clin Vaccine Immunol (2006) 0.97
CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol (2003) 0.97
Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res (2010) 0.96
Virally infected mouse liver endothelial cells trigger CD8+ T-cell immunity. Gastroenterology (2009) 0.95
Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. J Leukoc Biol (2009) 0.94
Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res (2009) 0.94
Indices of cardiovascular function derived from peripheral pulse wave analysis using radial applanation tonometry: a measurement repeatability study. Vasc Med (2007) 0.94
Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol (2009) 0.93
Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res (2010) 0.92
Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur J Immunol (2011) 0.92
Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells (2013) 0.92
5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology (2011) 0.92
CpG oligonucleotides: novel regulators of osteoclast differentiation. FASEB J (2002) 0.92
RIG-I detects triphosphorylated RNA of Listeria monocytogenes during infection in non-immune cells. PLoS One (2013) 0.92
Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. J Allergy Clin Immunol (2009) 0.91
Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood (2007) 0.91
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol (2010) 0.90
Stressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions. Front Mol Neurosci (2012) 0.90